RÉSUMÉ
OBJECTIVE: To explore the optimal methods for the reconstruction and preservation of the glans after partial penis resection in the treatment of early-stage penile cancer. METHODS: Between January 2012 and June 2015, we treated 6 cases of early- stage penile cancer by partial penis resection, inner thigh skin graft, and glans reconstruction and followed them up for 0.5-3 years. RESULTS: The length of the penis before and after operation was ([6.5 ± 1.2] vs [4.5 ± 1.8] cm) in the flaccid state and ([12.8 ± 2.3] vs [9.1 ± 2.1] cm) in the erectile state. The sense of the reconstructed glans was completely recovered at 3 months after surgery. The glans skin was pale red and soft, nearly normal at 12 months, with no obvious graft contracture or scar formation. All the patients achieved normal erection and their partners were satisfied with their intercourse. No recurrence or metastasis was observed. CONCLUSION: The strategy of partial penis resection, inner thigh skin graft and glans reconstruction, simple, effective, and with few complications, is one of the best treatments of early-stage penile cancer, which not only ensures radical removal of the tumor but also maximally reserves the function of the organ.
Sujet(s)
Tumeurs du pénis/chirurgie , Pénis/chirurgie , , Transplantation de peau , Humains , Mâle , CuisseRÉSUMÉ
OBJECTIVE: To investigate the effect of transforming growth factor-ß1 (TGF-ß1) on the expression of Fascin1 protein and its impact on cell invasion and metastasis in human renal carcinoma. METHODS: Renal tissue slices of 52 cases when undergoing radical nephrectomy were collected to be the observation group, and the normal renal tissues of 23 cases when undergoing nephrectomy due to trauma were collected to be the control group. The expressions of TGF-ß1 and Fascin1 were measured by immunohistochemical staining. Human renal carcinoma 786-0 cell line was selected as the study subject. The cells were divided into six groups including NT (no transfection), si-NC (transfection with pGenesil-1-con) si-Fascin1 (transfection with pGen-1-FSCN1) groups, and three corresponding groups: NT, si-NC and si-Fascin1 groups treated with TGF-ß1. RT-qPCR, Western-Blot, Transwell, and flow cytometry method were used in this study. RESULTS: The expressions of TGF-ß1 and Fascin1 in the observation group were significantly higher than those in the control group. The expression of TGF-ß1 was positively correlated with that of Fascin1. After 24 and 48h of treatment with TGF-ß1 (10ng/mL), the invasive and metastatic abilities of the 786-0 cells in the NT and si-NC groups were higher than those before the treatment (P<0.05). Comparing the three groups before TGF-ß1 treatment, the invasive and metastatic ability of 786-0 cells in the si-Fascin1 were significantly lower than those in the NT group and si-NC group (P<0.05). CONCLUSION: TGF-ß1 could induce the expressions of 786-0 Fascin1 mRNA and protein and thus improve the invasive and metastatic ability of human 786-0 renal carcinoma cell.
Sujet(s)
Néphrocarcinome/métabolisme , Protéines de transport/métabolisme , Tumeurs du rein/métabolisme , Protéines des microfilaments/métabolisme , Facteur de croissance transformant bêta-1/physiologie , Adulte , Sujet âgé , Apoptose , Néphrocarcinome/secondaire , Protéines de transport/génétique , Lignée cellulaire tumorale , Mouvement cellulaire , Femelle , Expression des gènes , Humains , Tumeurs du rein/anatomopathologie , Mâle , Protéines des microfilaments/génétique , Adulte d'âge moyen , Invasion tumorale , Activation de la transcriptionRÉSUMÉ
Prostate cancer (PCa) remains the second leading cause of cancer diagnosis worldwide. Early diagnosis and treatment of PCa is critical since the long-term prognosis is excellent in patients with tumors confined to the prostate gland. The current meta-analysis investigates the diagnostic value of resistive index (RI) measurement using color Doppler ultrasound in patients with PCa. Electronic literature databases were exhaustively searched for relevant studies published prior to May 31, 2014. Nine studies met our predetermined inclusion criteria for the present meta-analysis. The methodologic quality of the selected studies was independently assessed by 2 reviewers based on Quality Assessment of Diagnostic Accuracy Studies tool. Our meta-analysis results showed that RI values were significantly higher in malignant prostate tissues compared to normal prostate tissues (standardized mean difference [SMD] 0.42, 95% confidence interval [CI] 0.12~0.73, p = 0.007) and benign prostate tissues (SMD 0.41, 95% CI 0.26~0.56, p<0.001). Subgroup analysis based on the diagnostic instruments used revealed that RI values were accurate in diagnosis of PCa when compared between malignant tissue vs normal tissue and malignant tissue vs benign tissue (all p<0.05). Taken together, our findings support the potential clinical applications of RI values in diagnosis of PCa.
Sujet(s)
Tumeurs de la prostate/vascularisation , Tumeurs de la prostate/imagerie diagnostique , Échographie-doppler couleur , Résistance vasculaire , Endosonographie , Humains , Mâle , Valeur prédictive des tests , Tumeurs de la prostate/anatomopathologie , Rectum , Plan de recherche/normesRÉSUMÉ
OBJECTIVE: To review and assess the update studies regarding selective serotonin reuptake inhibitors (SSRIs) in the treatment of premature ejaculation (PE) and then provide practical recommendations and possible mechanisms concerning state of the art knowledge for the use of SSRIs in alleviating PE. DATA SOURCES: Using the Medline, 48 articles published from January 1st, 1996 to August 1st, 2006 concerning the use of SSRIs and their possible mechanisms in alleviating PE were found and reviewed. STUDY SELECTION: PE, rapid ejaculation, early ejaculation and SSRIs were employed as the keywords, and relevant articles about the use of SSRIs and their possible mechanisms in the treatment of PE were selected. RESULTS: Many kinds of SSRIs, such as fluoxetine, sertraline, paroxetine and citalopram, have widely been employed to treat PE. However, their effects are moderate and there is no a universal agreement about the kind, dose, protocol and duration. Dapoxetine, as the first prescription treatment of PE, may change this bottle-neck situation. SSRIs are suggested to be used in young men with lifelong PE, and acquired PE when etiological factors are removed but PE still exists. Phosphodiesterase 5 inhibitors (PDE(5)-Is) are suggested to be employed alone or combined with SSRIs when SSRIs fail to treat PE or sexual dysfunction associated with SSRIs occurs. The protocol of taking drugs on demand based on taking them daily for a suitable period is proposed to be chosen firstly. The possible mechanisms include increasing serotonergic neurotransmission and activating 5-hydroxytryptamine 2C (5-HT(2C)) receptors, then switching the ejaculatory threshold to a higher level, decreasing the penile sensitivity and their own effect of antidepression. CONCLUSION: The efficacies of the current SSRIs are moderate in the treatment of PE and they have not been approved by the FDA, therefore new SSRI like dapoxetine needs to be further evaluated.
Sujet(s)
Éjaculation/effets des médicaments et des substances chimiques , Inbiteurs sélectifs de la recapture de la sérotonine/usage thérapeutique , Troubles sexuels d'origine physiologique/traitement médicamenteux , Essais cliniques comme sujet , Humains , Mâle , Pipérazines/usage thérapeutique , Purines/usage thérapeutique , Inbiteurs sélectifs de la recapture de la sérotonine/effets indésirables , Inbiteurs sélectifs de la recapture de la sérotonine/pharmacologie , Citrate de sildénafil , Sulfones/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Recently, sildenafil has been demonstrated to be effective in treating premature ejaculation (PE). However, these studies ignored female factors and could not exclude the probability of drug interaction when combined with paroxetine. Therefore, the aim of this study was to evaluate the efficacy and safety of sildenafil alone in the treatment of primary PE, taking female factors into consideration. METHODS: One hundred and eighty potent men with primary PE were randomly divided into three groups and followed up for 6 months. Group A were treated with 50 mg sildenafil as needed, group B with 20 mg paroxetine daily and group C with squeeze technique daily. Intravaginal ejaculatory latency time (IELT), PE grade, intercourse satisfactory score (ISS), frequency of intercourse, and adverse effects of drugs were recorded before treatment, and 3 and 6 months after treatment. RESULTS: Compared with pretreatment, the three groups had significant differences in all the parameters after 3 or 6 months treatment, except the frequency of intercourse in Group C (all P = 0.00). However, there were no significant differences between 3 and 6 months. Compared with paroxetine and squeeze technique, after 3 or 6 months, sildenafil had significant differences in all the parameters (all P = 0.00). After 6 months, 1.7%, 18.3% and 36.7% patients in groups A, B and C, respectively, withdrew from the study and 86.7%, 60.0% and 45.0% patients, respectively, wanted to be treated further with the original administration, and this was statistically significant (both P = 0.00). CONCLUSION: Sildenafil is very effective and safe to treat PE, and has much higher efficacy than paroxetine and squeeze technique.
Sujet(s)
Éjaculation , Inhibiteurs de la phosphodiestérase/usage thérapeutique , Pipérazines/usage thérapeutique , Troubles sexuels d'origine physiologique/traitement médicamenteux , Sulfones/usage thérapeutique , Adolescent , Adulte , Coït , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Satisfaction personnelle , Études prospectives , Purines/usage thérapeutique , Temps de réaction , Citrate de sildénafilRÉSUMÉ
Drugs for the treatment of premature ejaculation (PE) are divided to two categories: oral drugs and local drugs. Oral drugs include antidepressive drugs, alpha-adrenoceptor blocking drugs, phosphodiesterase type V blocking drugs and Chinese herbal medicine. Local drugs include local surface drugs, intracavernosal injective drugs and local urethra drugs. Antidepressive drugs are extensively used, which have moderate efficacy, relatively more side effects and high recurrence rate; alpha-adrenoceptor blocking drugs are seldom used and are less effective than antidepressive drugs; phosphodiesterase type V blocking drugs like sildenafil have good efficacy and few side-effects and are worthy to be studied further. Local surface drugs like SS-Cream have good efficacy and few side-effects and are worthy to be applied and promoted; local urethral drugs like MUSE and Befar may become a new method to treat PE after being further studied. Medication for premature ejaculation shall be made specific and suitable as much as for each individual patient.
Sujet(s)
Éjaculation/effets des médicaments et des substances chimiques , Antagonistes alpha-adrénergiques/usage thérapeutique , Antidépresseurs/usage thérapeutique , Médicaments issus de plantes chinoises/usage thérapeutique , Humains , Mâle , Inhibiteurs de la phosphodiestérase/usage thérapeutiqueRÉSUMÉ
OBJECTIVES: To evaluate the relationship between the operative methods and the therapeutic results of the patients with hypospadias. METHODS: Nine operative types and different tissue materials taken in hypospadias operations in the past 12 years were retrospectively analyzed. RESULTS: The operative types and tissue materials had significantly effects on the therapeutic results besides the clinical experience of the operators. The cure rates of Tunneltron Urethroplasty, Preputial island flap urethroplasty and Bladder mucosa graft urethroplasty were 86.4%, 83.3% and 83.0% respectively. CONCLUSIONS: All the nine types and different tissue materials of Hypospadias operations have its own advantages and disadvantages. They are worth further study and improvement.